文献速递胃肠外科围术期管理与 ERAS

符合扩大标准的pT1acN0M0胃腺癌患者内镜与胃切除术后的长期生存结局相当

Comparable long-term survival outcomes after endoscopic and gastrectomy treatment of pT1acN0M0 gastric adenocarcinoma in patients who met the expanded criteria.
PubMed 文献 · Surg Endosc · 2024-06-10

本研究基于SEER数据库的回顾性队列,纳入314例符合日本扩大标准的pT1acN0M0胃腺癌患者,其中46例接受内镜治疗、268例接受胃切除术。多因素Cox分析和竞争风险模型均显示两组癌症特异性死亡风险无显著差异(调整HR 1.18,95%CI 0.40-3.49,P=0.766;SHR 1.12,95%CI 0.38-3.29,P=0.845),与淋巴结检出数>15枚的胃切除组比较亦无显著差异。作者认为西方符合扩大标准的此类患者可考虑内镜治疗,但需前瞻性研究证实。

要点

  • 符合日本扩大标准的pT1acN0M0胃腺癌中,内镜治疗与胃切除术的癌症特异性死亡风险无显著差异(调整HR 1.18,95%CI 0.40-3.49)。
  • 与淋巴结检出数>15枚的胃切除组比较,内镜治疗生存结局仍相当(调整HR 1.55,95%CI 0.44-5.49,P=0.499)。
  • 作者认为西方符合扩大标准的此类患者可考虑内镜治疗,但需前瞻性研究证实。

核心结论

  • 西方pT1acN0M0胃腺癌患者若符合日本扩大标准,可考虑内镜治疗;但需前瞻性研究证实。

研究设计与样本

  • 基于监测、流行病学和最终结果(SEER)项目的回顾性队列研究,共纳入314例符合扩大标准的pT1acN0M0胃腺癌患者,其中46例接受内镜治疗、268例接受胃切除术。

主要发现

  • 多因素Cox分析显示内镜治疗组与胃切除组的癌症特异性死亡风险无显著差异(调整HR 1.18,95%CI 0.40-3.49,P=0.766)。
  • 多因素竞争风险模型显示两组癌症特异性死亡风险无显著差异(SHR 1.12,95%CI 0.38-3.29,P=0.845)。
  • 与淋巴结检出数>15枚的胃切除组比较,内镜治疗组生存结局仍相当(调整HR 1.55,95%CI 0.44-5.49,P=0.499;SHR 1.47,95%CI 0.44-4.88,P=0.532)。

关键数值与推荐

  • 内镜治疗组46例,胃切除组268例,均符合日本扩大标准。
  • 癌症特异性死亡:内镜治疗组 vs 胃切除组调整HR 1.18(95%CI 0.40-3.49,P=0.766)。
  • 癌症特异性死亡:内镜治疗组 vs 胃切除组SHR 1.12(95%CI 0.38-3.29,P=0.845)。
  • 与淋巴结检出数>15枚的胃切除组比较:调整HR 1.55(95%CI 0.44-5.49,P=0.499),SHR 1.47(95%CI 0.44-4.88,P=0.532)。

临床怎么用

  • 作者认为,西方pT1acN0M0胃腺癌患者若符合日本扩大标准,可考虑内镜治疗;但需前瞻性研究证实。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Whether the Western pT1acN0M0 gastric cancer (GC) patients who met the Japanese expanded criteria could be the candidates for endoscopic treatment (ET) remains unclear because of unknown long-term survival outcomes. METHODS: A retrospective cohort study using data from the Surveillance, Epidemiology, and End Results (SEER) program was performed. The survival differences between pT1acN0M0 gastric adenocarcinoma patients who received ET or gastrectomy treatment (GT) were evaluated using multivariate survival analysis. RESULTS: A total of 314 pT1acN0M0 gastric adenocarcinoma patients who met the expanded criteria were included, 46 patients received ET and 268 patients received GT. pT1acN0M0 gastric adenocarcinoma patients met the expanded criteria underwent ET experienced a similar hazard of cancer-specific death compared with those underwent GT both in the multivariate Cox survival analysis (adjusted hazard ratio [HR]; 1.18, 95% confidence interval [CI] 0.40-3.49; P = 0.766) and the multivariate competing risk model (subdistribution HR [SHR], 1.12, 95% CI 0.38-3.29; P = 0.845). The result that pT1acN0M0 gastric adenocarcinoma patients met the expanded criteria underwent ET experienced comparable survival outcomes to those who underwent GT did not change even compared with those who underwent GT with > 15 lymph nodes examined (adjusted HR, 1.55, 95% CI 0.44-5.49; P = 0.499; SHR, 1.47, 95% CI 0.44-4.88; P = 0.532). CONCLUSIONS: The ET can be considered in Western pT1acN0M0 gastric adenocarcinoma patients who met the Japanese expanded criteria. However, a prospective study should be warranted.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. JingRu C, GuoHui M, LiLi G, et al. Comparable long-term survival outcomes after endoscopic and gastrectomy treatment of pT1acN0M0 gastric adenocarcinoma in patients who met the expanded criteria. Surg Endosc. 2024. PMID: 38858250. doi:10.1007/s00464-024-10945-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。